[stock_market_widget type=”card” template=”basic2″ assets=”ANL” realtime=”true” api=”yahoo-finance”]
A drug does not have to be taken every single day to work. That simple idea sits behind a clinical trial update from Adlai Nortye Ltd. (NASDAQ: ANL), which reported that its first patient in the United States has now received AN9025 on a once weekly schedule, rather than the daily regimen that has defined most trials in this drug class so far.
AN9025 belongs to a group of medicines known as pan RAS(ON) inhibitors. RAS genes are among the most commonly mutated genes in human cancer, and when they malfunction they push cells to grow and divide without normal restraint. Drugs that block RAS activity have become one of the more closely watched areas of oncology research over the past several years, and AN9025 is Adlai Nortye’s entry into that space, designed to work across a broad range of RAS mutations rather than just one specific type.
Until now, patients in the ongoing Phase 1 trial received AN9025 daily, a schedule known in clinical shorthand as QD. The company has now opened a second arm using a weekly schedule, or QW, and dosed its first U.S. patient under that approach. Dr. Archie Tse, President and Head of Research and Development at Adlai Nortye, said the milestone reflects a deliberate strategy to test whether spacing out doses could actually improve the drug’s performance rather than simply making it more convenient to take.
The reasoning comes from preclinical data, meaning results gathered before human testing began. According to the company, giving normal, healthy tissue a break between doses while still suppressing RAS signaling in tumors could widen what researchers call the therapeutic window. In practical terms, that is the gap between a dose strong enough to fight cancer and a dose that causes unacceptable side effects. A wider window could theoretically allow doctors to give higher doses, improve how well patients tolerate treatment, or make it easier to combine AN9025 with other cancer therapies down the road.
This is still early-stage research. The Phase 1 trial is a first in human, multicenter, open label study, meaning both researchers and patients know which treatment is being given, and its primary purpose is to establish safety, how the body processes the drug, and early signs of anti tumor activity in people with advanced or metastatic solid tumors carrying RAS mutations. With the QW arm now enrolling alongside the original QD arm, Adlai Nortye is effectively running two parallel experiments to see which dosing pattern, or perhaps both, moves forward into later stages of development.
The trial itself is a joint effort. Adlai Nortye is running it in collaboration with Jiangsu Aosaikang Pharmaceutical Co. Ltd., referred to as ASK Pharm, under a license agreement signed in late 2025. Adlai Nortye holds rights to AN9025 outside mainland China, while ASK Pharm holds rights within mainland China, Hong Kong, and Macao. That structure allows the two companies to pursue global development while dividing commercial territory.
Investors watching the RAS inhibitor space will not have to wait too long for more concrete evidence. The company said it still plans to release initial Phase 1 dose escalation data from the daily arm in the first half of 2027, with the possibility of an early look at results from the weekly arm as well. Until then, AN9025 remains one of several experimental RAS targeted drugs working its way through early trials, alongside the company’s broader pipeline, which includes an antibody drug conjugate called AN4035 and two immunotherapy candidates aimed at the PD-1/L1 pathway. Whether weekly dosing turns out to be a meaningful improvement or simply an alternative worth ruling out, the coming data readouts should offer the first real test of the idea.
